Bayer Commits $2.35M Non‑dilutive Funding to Voyageur Pharmaceuticals for Iodine Extraction Technology

Deal Summary

Bayer has committed $2.35 million in non‑dilutive funding to Voyageur Pharmaceuticals Ltd. to advance feasibility work and field‑scale testing of its iodine extraction technology, as part of a partnership announced earlier this year. The agreement also contemplates a future iodine offtake arrangement upon meeting technical milestones, underscoring Bayer’s validation of Voyageur’s critical‑mineral strategy for healthcare.